Ingrid Bakalorz Blubaugh, DO
Family Medicine · Palmyra, PANPI 1548676364
Payments from drug & device makers
Across 412 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$923
- GSK$885
- AbbVie$851
- AstraZeneca$679
- Lilly USA, LLC$608
- Pfizer$365
- plus $2K from 32 others
What the payments were for
- Food & beverage$6,50499%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $923 |
| GSK | 79 | $885 |
| AbbVie(2 entities) | 54 | $851 |
| AstraZeneca | 36 | $679 |
| Lilly USA, LLC | 36 | $608 |
| Pfizer | 26 | $365 |
| Boehringer Ingelheim | 21 | $331 |
| Amgen | 15 | $225 |
| Astellas Pharma US Inc | 7 | $207 |
| Johnson & Johnson | 12 | $202 |
| E.r. Squibb & Sons, L.L.C. | 10 | $186 |
| Sanofi-aventis U.S. LLC | 10 | $158 |
| Abbott | 5 | $98 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $89 |
| Axsome Therapeutics, Inc. | 4 | $83 |
| Novartis | 4 | $77 |
| Merck | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Dexcom, Inc. | 2 | $54 |
| Exact Sciences | 2 | $45 |
| Sanofi Pasteur Inc. | 2 | $44 |
| Cequr Corporation | 1 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Almatica Pharma LLC | 1 | $29 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Eisai Inc. | 1 | $26 |
| Amarin Pharma, Inc. | 2 | $25 |
| Boston Scientific | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Mannkind Corporation | 1 | $14 |
| Bayer | 1 | $14 |
How this compares
$6,603 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $131,728 |
| EliquisApixaban | 68 | $82,127 |
| JardianceEmpagliflozin | 41 | $60,302 |
| Repatha SureclickEvolocumab | 56 | $57,596 |
| XareltoRivaroxaban | 27 | $29,691 |
| FarxigaDapagliflozin Propanediol | 27 | $28,527 |
| MounjaroTirzepatide | 14 | $17,466 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $17,305 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $15,187 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $14,259 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $13,313 |
| TrulicityDulaglutide | 12 | $11,291 |
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $8,633 |
| Atorvastatin Calcium | 561 | $5,515 |
| Omeprazole | 266 | $3,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $923 | $131,72867 claims |
| PfizerEliquis | $365 | $82,12768 claims |
| Boehringer IngelheimJardiance, Synjardy | $331 | $68,93554 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $679 | $43,71447 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $885 | $30,61833 claims |
| Johnson & JohnsonXarelto | $202 | $29,69127 claims |
| Lilly USA, LLCMounjaro, Trulicity | $608 | $28,75726 claims |
| MerckJanumet | $63 | $14,25917 claims |
| AbbVieSynthroid | $851 | $2,79642 claims |
| Almatica Pharma LLCSertraline Hcl | $29 | $1,306134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Palmyra
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.